Refine
Year of publication
Document Type
- Journal article (7325)
- Doctoral Thesis (2750)
- Book article / Book chapter (133)
- Conference Proceeding (108)
- Preprint (104)
- Working Paper (66)
- Review (43)
- Report (27)
- Master Thesis (25)
- Book (20)
- Other (13)
- Bachelor Thesis (5)
- Jahresbericht (1)
- Habilitation (1)
- Study Thesis (term paper) (1)
Language
- English (10622) (remove)
Keywords
- Toxikologie (119)
- Medizin (99)
- inflammation (88)
- Biochemie (85)
- Psychologie (85)
- cancer (71)
- Organische Chemie (68)
- gene expression (68)
- Anorganische Chemie (66)
- Maus (64)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (1854)
- Graduate School of Life Sciences (767)
- Physikalisches Institut (573)
- Institut für Psychologie (465)
- Neurologische Klinik und Poliklinik (363)
- Institut für Organische Chemie (353)
- Institut für Anorganische Chemie (352)
- Medizinische Klinik und Poliklinik I (342)
- Institut für Molekulare Infektionsbiologie (341)
- Institut für Informatik (337)
Schriftenreihe
- Cultural Animal Studies, Band 3 (24)
- Berichte aus der Informatik (1)
- Deuterocanonical and Cognate Literature Studies (1)
- Deuterocanonical and Cognate Literature Yearbook (1)
- Frontiers in Psychology (2023) 14:1219915. https://doi.org/10.3389/fpsyg.2023.1219915 (1)
- Frontiers in Public Health (2023) 11:1153088. https://doi.org/10.3389/fpubh.2023.1153088 (1)
- International Archives of the History of Ideas / Archives internationales d’histoire des idées 242 (1)
- Methods in Molecular Biology 2533 (1)
- Methods in Molecular Biology; 2643 (1)
- Redox Biology (2024) 70:103011. DOI: 10.1016/j.redox.2023.103011 (1)
Sonstige beteiligte Institutionen
- VolkswagenStiftung (24)
- Johns Hopkins School of Medicine (17)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (7)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (5)
- Fraunhofer-Institut für Silicatforschung ISC (5)
- Helmholtz Institute for RNA-based Infection Research (HIRI) (5)
- Johns Hopkins University School of Medicine (5)
- Wilhelm-Conrad-Röntgen-Forschungszentrum für komplexe Materialsysteme (5)
- Bernhard-Heine-Centrum für Bewegungsforschung (4)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (4)
ResearcherID
- B-1911-2015 (1)
- B-4606-2017 (1)
- C-2593-2016 (1)
- D-1221-2009 (1)
- D-1250-2010 (1)
- I-5818-2014 (1)
- J-8841-2015 (1)
- M-1240-2017 (1)
- N-2030-2015 (1)
- N-3741-2015 (1)
EU-Project number / Contract (GA) number
- 669054 (46)
- 701983 (38)
- 602805 (25)
- 682586 (23)
- 646737 (22)
- 728018 (15)
- 224631 (10)
- 288566 (10)
- 602133 (10)
- 787937 (9)
- 244090 (7)
- 259867 (6)
- 309962 (6)
- 614623 (6)
- 643051 (6)
- 677819 (6)
- 823881 (6)
- 101007642 (5)
- 241778 (5)
- 311781 (5)
- 223153 (4)
- 226852 (4)
- 250194 (4)
- 311932 (4)
- 336012 (4)
- 336305 (4)
- 607051 (4)
- 617989 (4)
- 654148 (4)
- 678119 (4)
- 766118 (4)
- 825575 (4)
- 848261 (4)
- 01EW1902 (3)
- 223138 (3)
- 223175 (3)
- 247919 (3)
- 261357 (3)
- 287320 (3)
- 289706 (3)
- 339306 (3)
- 667302 (3)
- 686070 (3)
- 721016 (3)
- 733297 (3)
- 759139 (3)
- 813871 (3)
- 824128 (3)
- 018741 (2)
- 201099 (2)
- 227632 (2)
- 245009 (2)
- 250320 (2)
- 262055 (2)
- 265432 (2)
- 268985 (2)
- 277775 (2)
- 281338 (2)
- 304617 (2)
- 305312 (2)
- 308377 (2)
- 312325 (2)
- 315877 (2)
- 316704 (2)
- 318798 (2)
- 320377 (2)
- 327199 (2)
- 335568 (2)
- 340983 (2)
- 503474 (2)
- 602300 (2)
- 618045 (2)
- 633983 (2)
- 636930 (2)
- 669830 (2)
- 680966 (2)
- 693023 (2)
- 721394 (2)
- 722046 (2)
- 754658 (2)
- 758985 (2)
- 761307 (2)
- 765937 (2)
- 847507 (2)
- 897276 (2)
- 946184 (2)
- 953327 (2)
- 011937 (1)
- 018696 (1)
- 026155 (1)
- 031A408B (1)
- 031A409B (1)
- 037220 (1)
- 037602 (1)
- 0800978 (1)
- 101003595 (1)
- 10100764 (1)
- 101015930 (1)
- 101016923 (1)
- 101030656 (1)
- 101034412 (1)
- 101041177 (1)
- 101045956 (1)
- 101052587 (1)
- 101065772 (1)
- 101069547 (1)
- 101076402 (1)
- 101079460 (1)
- 115300 (1)
- 115525 (1)
- 18741 (1)
- 19-COP-0031 (1)
- 20100317 (1)
- 20100407 (1)
- 201024 (1)
- 201052 (1)
- 2016 FGR 0053 (1)
- 201962 (1)
- 2020010013 (1)
- 202088 (1)
- 202213 (1)
- 203291 (1)
- 211078 (1)
- 212372 (1)
- 212525 (1)
- 214469 (1)
- 216027 (1)
- 216886 (1)
- 222719 (1)
- 222943 (1)
- 223044 (1)
- 224635 (1)
- 227159 (1)
- 229289 (1)
- 229294 (1)
- 229571 (1)
- 230331-PROPEREMO (1)
- 232944 (1)
- 241447 (1)
- 241592 (1)
- 241719 (1)
- 241909 (1)
- 242175 (1)
- 242175-VascuBone (1)
- 242175‐VascuBone (1)
- 242257 (1)
- 243964 (1)
- 247447 (1)
- 249177 (1)
- 249929 (1)
- 250194-Carnivorom (1)
- 253511 (1)
- 257531 (1)
- 259735 (1)
- 259753 (1)
- 260338 (1)
- 260464 (1)
- 260986 (1)
- 261474 (1)
- 261492 (1)
- 26230120009 (1)
- 262773 (1)
- 266777 (1)
- 267436 (1)
- 268962 (1)
- 270089 (1)
- 270212 (1)
- 274769 (1)
- 27731 (1)
- 278864 (1)
- 278864-2 (1)
- 279062 (1)
- 286213 (1)
- 289442 (1)
- 289600 (1)
- 290605 (1)
- 291377 (1)
- 291840 (1)
- 294683 (1)
- 296679 (1)
- 297557 (1)
- 303674 (1)
- 304961 (1)
- 305653 (1)
- 306387 (1)
- 306447 (1)
- 307701 (1)
- 307955 (1)
- 311575 (1)
- 312147 (1)
- 314911 (1)
- 316633 (1)
- 316790 (1)
- 318987 (1)
- 320570 (1)
- 322865 (1)
- 324612 (1)
- 339728 (1)
- 340602 (1)
- 506675 (1)
- 517836 (1)
- 602102 (1)
- 602531 (1)
- 602812 (1)
- 604391 (1)
- 606950 (1)
- 609,020 (1)
- 610307 (1)
- 613931 (1)
- 615613 (1)
- 616346 (1)
- 634361 (1)
- 638536 (1)
- 638988 (1)
- 639445 (1)
- 640012 (1)
- 641458 (1)
- 641833 (1)
- 643238 (1)
- 644076 (1)
- 645993 (1)
- 647281 (1)
- 649124 (1)
- 654000 (1)
- 660375 (1)
- 667421 (1)
- 667787 (1)
- 668036 (1)
- 668353 (1)
- 668679 (1)
- 677302 (1)
- 679288 (1)
- 681103 (1)
- 686271 (1)
- 692185 (1)
- 695376 (1)
- 696802 (1)
- 703227 (1)
- 716344 (1)
- 720270 (1)
- 722064 (1)
- 723770 (1)
- 725832 (1)
- 739593 (1)
- 741491 (1)
- 755523 (1)
- 764860 (1)
- 776019 (1)
- 810850 (1)
- 812968 (1)
- 818182 (1)
- 819800 (1)
- 834709 (1)
- 835102) (1)
- 836421 (1)
- 840741 (1)
- 853546 (1)
- 853988 (1)
- 862665 (1)
- 871158 (1)
- 874758 (1)
- 874827 (1)
- 955974 (1)
- 956414 (1)
- 956548 (1)
- 965286 (1)
- BWF/H/52228/2012/13.10.10-1/3.4,6 (1)
- CP22/00082 (1)
- CoG 721016–HERPES (1)
- ERC-2013-StG-336305 (1)
- ERC-2016-CoG 721016-HERPES (1)
- ERC-2018-ADG/NCI-CAD (1)
- ERC335568 (1)
- ESF-ZDEX 4.0 (1)
- ESF_14-BM-A55-0005_16 (1)
- EU (FP7/ 2007-2013) (1)
- EU-1650-0006 (1)
- EU250194 (1)
- FKZ01EW1902 (1)
- FOOD‑CT‑2004‑506378 (1)
- FP7-ICT MINIMAL (1)
- FP7/2007-2013 (1)
- HEALTH-F2-2009-241778 (1)
- HEALTHF2- 2008-201099 (1)
- LIFE12 BIO/AT/000143 (1)
- LIFE20 NAT/AT/000049 (1)
- LaserLab Europe (LLC001917) (1)
- PI21/00314 (1)
- PIEF-GA-2013-623006 (1)
- PITN-GA-2012-316704 (1)
- PTQ2020-011372 (1)
- QLK1-2001-01614 (1)
- RTI2018-093747-B-10 (1)
- ZAM 5-85018031 (1)
In DNA-encoded library synthesis, amine-substituted building blocks are prevalent. We explored isocyanide multicomponent reactions to diversify DNA-tagged amines and reported the Ugi-azide reaction with high yields and a good substrate scope. In addition, the Ugi-aza-Wittig reaction and the Ugi-4-center-3-component reaction, which used bifunctional carboxylic acids to provide lactams, were explored. Five-, six-, and seven-membered lactams were synthesized from solid support-coupled DNA-tagged amines and bifunctional building blocks, providing access to structurally diverse scaffolds.
The binding of drugs to plasma proteins is an important process in the human body and has a significant influence on pharmacokinetic parameter. Human serum albumin (HSA) has the most important function as a transporter protein. The binding of ketamine to HSA has already been described in literature, but only of the racemate. The enantiomerically pure S-ketamine is used as injection solution for induction of anesthesia and has been approved by the Food and Drug Administration for the therapy of severe depression as a nasal spray in 2019. The question arises if there is enantioselective binding to HSA. Hence, the aim of this study was to investigate whether there is enantioselective binding of S-and R-ketamine to HSA or not. Ultrafiltration (UF) followed by chiral capillary electrophoretic analysis was used to determine the extent of protein binding. Bound fraction to HSA was 71.2 % and 64.9 % for enantiomerically pure R- and S-ketamine, respectively, and 66.5 % for the racemate. Detailed binding properties were studied by Saturation Transfer Difference (STD)-, waterLOGSY- and Carr-Purcell-Meiboom-Gill (CPMG)-NMR spectroscopy. With all three methods, the aromatic ring and the N-methyl group could be identified as the structural moieties most strongly involved in binding of ketamine to HSA. pK\(_{aff}\) values determined using UF and NMR indicate that ketamine is a weak affinity ligand to HSA and no significant differences in binding behavior were found between the individual enantiomers and the racemate.
The hallmark oncoprotein Myc is a major driver of tumorigenesis in various human cancer entities. However, Myc’s structural features make it challenging to develop small molecules against it. A promising strategy to indirectly inhibit the function of Myc is by targeting its interactors. Many Myc-interacting proteins have reported scaffolding functions which are difficult to target using conventional occupancy- driven inhibitors. Thus, in this thesis, the proteolysis targeting chimera (PROTAC) approach was used to target two oncoproteins interacting with Myc which promote the oncogenicity of Myc, Aurora-A and WDR5. PROTACs are bifunctional small molecules that bind to the target protein with one ligand and recruit a cellular E3- ligase with the other ligand to induce target degradation via the ubiquitin- proteasome system. So far, the most widely used E3-ligases for PROTAC development are Cereblon (CRBN) and von Hippel–Lindau tumor suppressor (VHL). Furthermore, there are cases of incompatibility between some E3-ligases and proteins to bring about degradation. Hence there is a need to explore new E3- ligases and a demand for a tool to predict degradative E3-ligases for the target protein in the PROTAC field.
In the first part, a highly specific mitotic kinase Aurora-A degrader, JB170, was developed. This compound utilized Aurora-A inhibitor alisertib as the target ligand and thalidomide as the E3-ligase CRBN harness. The specificity of JB170 and the ternary complex formation was supported by the interactions between Aurora-A and CRBN. The PROTAC-mediated degradation of Aurora-A induced a distinct S- phase defect rather than mitotic arrest, shown by its catalytic inhibition. The finding demonstrates that Aurora-A has a non-catalytic role in the S-phase. Furthermore, the degradation of Aurora-A led to apoptosis in various cancer cell lines.
In the second part, two different series of WDR5 PROTACs based on two protein- protein inhibitors of WDR5 were evaluated. The most efficient degraders from both series recruited VHL as a E3-ligase and showed partial degradation of WDR5. In addition, the degradation efficiency of the PROTACs was significantly affected by the linker nature and length, highlighting the importance of linker length and composition in PROTAC design. The degraders showed modest proliferation defects at best in cancer cell lines. However, overexpression of VHL increased the degradation efficiency and the antiproliferative effect of the PROTACs.
In the last part, a rapamycin-based assay was developed to predict the degradative E3-ligase for a target. The assay was validated using the WDR5/VHL and Aurora- A/CRBN pairs. The result that WDR5 is degraded by VHL but not CRBN and Aurora-A is degraded by CRBN, matches observations made with PROTACs. This technique will be used in the future to find effective tissue-specific and essential E3-ligases for targeted degradation of oncoproteins using PROTACs.
Collectively, the work presented here provides a strategy to improve PROTAC development and a starting point for developing Aurora-A and WDR5 PROTACs for cancer therapy.
1,1,2-trifluoroethene (HFO-1123) is intended for use as a refrigerant. Inhalation studies on HFO-1123 in rats suggested a low potential for toxicity, with no-observed-adverse-effect levels greater then 20,000 ppm. However, single inhalation exposure of Goettingen Minipigs and New Zealand White Rabbits resulted in mortality. It was assumed that conjugation of HFO-1123 with glutathione, via glutathione S-transferase, gives rise to S-(1,1,2-trifluoroethyl)-L-glutathione (1123-GSH), which is then transformed to the corresponding cysteine S-conjugate (S-(1,1,2-trifluoroethyl)-L-cysteine, 1123-CYS). Subsequent beta-lyase mediated cleavage of 1123-CYS may result in monofluoroacetic acid, a potent inhibitor of aconitase. Species-differences in 1123-GSH formation and 1123-CYS cleavage to MFA may explain species-differences in HFO-1123 toxicity.
This study was designed to test the hypothesis, that GSH-dependent biotransformation and subsequent beta-lyase mediated formation of monofluoroacetic acid, a potent inhibitor of aconitase in the citric acid cycle, may play a key role in HFO-1123 toxicity and to evaluate if species-differences in the extent of MFA formation may account for the species-differences in HFO-1123 toxicity. The overall objective was to determine species-differences in HFO-1123 biotransformation in susceptible vs. less susceptible species and humans as a basis for human risk assessment.
To this end, in vitro biotransformation of HFO-1123 and 1123-CYS was investigated in renal and hepatic subcellular fractions of mice, rats, humans, Goettingen Minipigs and NZW Rabbits. Furthermore, cytotoxicity and metabolism of 1123-CYS was assessed in cultured renal epithelial cells. Enzyme kinetic parameters for beta-lyase mediated cleavage of 1123-CYS in renal and hepatic cytosolic fractions were determined, and 19F-NMR was used to identify fluorine containing metabolites arising from 1123-CYS cleavage. Quantification of 1123-GSH formation in hepatic S9 fractions after incubation with HFO-1123 was performed by LC-MS/MS and hepatic metabolism of HFO-1123 was monitored by 19F-NMR.
Rates of 1123-GSH formation were increased in rat, mouse and NZW Rabbit compared to human and Goettingen hepatic S9, indicating increased GSH dependent biotransformation in rats, mouse and NZW Rabbits. NZW Rabbit hepatic S9 exhibited increased 1123-GSH formation in the presence compared to the absence of acivicin, a specific gamma-GT inhibitor. This indicates increased gamma-GT mediated cleavage of 1123-GSH in NZW Rabbit hepatic S9 compared to the other species. 19F-NMR confirmed formation of 1123-GSH as the main metabolite of GSH mediated biotransformation of HFO-1123 in hepatic S9 fractions next to F-. Increased F- formation was detected in NZW Rabbit and Goettingen Minipig hepatic S9 in the presence of an NADPH regenerating system, indicating a higher rate of CYP-450 mediated metabolism in these species. Based on these findings, it is possible that CYP-450 mediated metabolism may contribute to HFO-1123 toxicity.
In contrast to the increased formation of 1123-GSH in rat, mouse and NZW Rabbit hepatic S9 (compared to human and Goettingen Minipig), enzyme kinetic studies revealed a significantly higher beta-lyase activity towards 1123-CYS in renal cytosol of Goettingen Minipigs compared to cytosol from rats, mice, humans and NZW Rabbits. However, beta-lyase cleavage in renal NZW Rabbit cytosol was slightly increased compared to rat, mouse and human renal cytosols. 19F-NMR analysis confirmed increased time-dependent formation of MFA in renal Goettingen Minipig cytosol and NZW Rabbit (compared to human and rat cytosolic fractions). Three structurally not defined MFA-derivatives were detected exclusively in NZW Rabbit and Goettingen Minipig cytosols. Also, porcine kidney cells were more sensitive to cytotoxicity of 1123-CYS compared to rat and human kidney cells.
Overall, increased beta-lyase mediate cleavage of 1123-CYS to MFA in Goettingen Minipig and NZW Rabbit kidney (compared to human and rat) may support the hypothesis that enzymatic cleavage by beta-lyases may account for the species-differences in HFO-1123 toxicity. However, the extent of GST mediated biotransformation in the liver as the initial step in HFO-1123 metabolism does not fully agree with this hypothesis, since 1123-GSH formation occurs at higher rates in rat, mouse and NZW Rabbit S9 as compared to the Goettingen Minipig.
Based on the inconsistencies between the extent of GST and beta-lyase mediated biotransformation of HFO-1123 obtained by this study, a decisive statement about an increased biotransformation of HFO-1123 in susceptible species with a direct linkage to the species-specific toxicity cannot be drawn. Resulting from this, a clear and reliable conclusion regarding the risk for human health originating from HFO-1123 cannot be made. However, considering the death of Goettingen Minipigs and NZW Rabbits after inhalation exposure of HFO-1123 at concentrations great than 500 ppm and greater than 1250 ppm, respectively, this indicates a health concern for humans under peak exposure conditions. For a successful registration of HFO-1123 and its use as a refrigerant, further in vitro and in vivo investigations addressing uncertainties in the species-specific toxicity of HFO-1123 are urgently needed.
DNA alkyltransferase and alkyltransferase-like family proteins are responsible for the repair of highly mutagenic and cytotoxic O\(^6\)-alkylguanine and O\(^4\)-alkylthymine bases in DNA. Their mechanism involves binding to the damaged DNA and flipping the base out of the DNA helix into the active site pocket in the protein. Alkyltransferases then directly and irreversibly transfer the alkyl group from the base to the active site cysteine residue. In contrast, alkyltransferase-like proteins recruit nucleotide excision repair components for O\(^6\)-alkylguanine elimination. One or more of these proteins are found in all kingdoms of life, and where this has been determined, their overall DNA repair mechanism is strictly conserved between organisms. Nevertheless, between species, subtle as well as more extensive differences that affect target lesion preferences and/or introduce additional protein functions have evolved. Examining these differences and their functional consequences is intricately entwined with understanding the details of their DNA repair mechanism(s) and their biological roles. In this review, we will present and discuss various aspects of the current status of knowledge on this intriguing protein family.
Highlights
• Synthesis of a new tracer molecule.
• Robust and easy screening method for a broad range of compound activities.
• FP assay validation considering limited use of starting material, DMSO tolerance, variation in incubation time and temperature.
• Possibility of extension to HTP assay.
Abstract
The macrophage infectivity potentiator (Mip) protein belongs to the immunophilin superfamily. This class of enzymes catalyzes the interconversion between the cis and trans configuration of proline-containing peptide bonds. Mip has been shown to be important for the virulence of a wide range of pathogenic microorganisms, including the Gram-negative bacterium Burkholderia pseudomallei. Small molecules derived from the natural product rapamycin, lacking its immunosuppression-inducing moiety, inhibit Mip's peptidyl-prolyl cis-trans isomerase (PPIase) activity and lead to a reduction in pathogen load in vitro. Here, a fluorescence polarization assay (FPA) to enable the screening and effective development of BpMip inhibitors was established. A fluorescent probe was prepared, derived from previous pipecolic scaffold Mip inhibitors labeled with fluorescein. This probe showed moderate affinity for BpMip and enabled a highly robust FPA suitable for screening large compound libraries with medium- to high-throughput (Z factor ∼ 0.89) to identify potent new inhibitors. The FPA results are consistent with data from the protease-coupled PPIase assay. Analysis of the temperature dependence of the probe's binding highlighted that BpMip's ligand binding is driven by enthalpic rather than entropic effects. This has considerable consequences for the use of low-temperature kinetic assays.
Anxious depression represents a subtype of major depressive disorder and is associated with increased suicidality, severity, chronicity and lower treatment response. Only a few studies have investigated the differences between anxious depressed (aMDD) and non-anxious depressed (naMDD) patients regarding treatment dosage, serum-concentration and drug-specific treatment response. In our naturalistic and prospective study, we investigated whether the effectiveness of therapy including antidepressants (SSRI, SNRI, NaSSA, tricyclics and combinations) in aMDD patients differs significantly from that in naMDD patients. In a sample of 346 patients, we calculated the anxiety somatization factor (ASF) and defined treatment response as a reduction (≥50%) in the Hamilton Depression Rating Scale (HDRS)-21 score after 7 weeks of pharmacological treatment. We did not observe an association between therapy response and the baseline ASF-scores, or differences in therapy outcomes between aMDD and naMDD patients. However, non-responders had higher ASF-scores, and at week 7 aMDD patients displayed a worse therapy outcome than naMDD patients. In subgroup analyses for different antidepressant drugs, venlafaxine-treated aMDD patients showed a significantly worse outcome at week 7. Future prospective, randomized-controlled studies should address the question of a worse therapy outcome in aMDD patients for different psychopharmaceuticals individually.
Dimethyl fumarate attenuates lymphocyte infiltration and reduces infarct size in experimental stroke
(2023)
Ischemic stroke is associated with exacerbated tissue damage caused by the activation of immune cells and the initiation of other inflammatory processes. Dimethyl fumarate (DMF) is known to modulate the immune response, activate antioxidative pathways, and improve the blood–brain barrier (BBB) after stroke. However, the specific impact of DMF on immune cells after cerebral ischemia remains unclear. In our study, male mice underwent transient middle cerebral artery occlusion (tMCAO) for 30 min and received oral DMF (15 mg/kg) or a vehicle immediately after tMCAO, followed by twice-daily administrations for 7 days. Infarct volume was assessed on T2-weighted magnetic resonance images on days 1 and 7 after tMCAO. Brain-infiltrating immune cells (lymphocytes, monocytes) and microglia were quantified using fluorescence-activated cell sorting. DMF treatment significantly reduced infarct volumes and brain edema. On day 1 after tMCAO, DMF-treated mice showed reduced lymphocyte infiltration compared to controls, which was not observed on day 7. Monocyte and microglial cell counts did not differ between groups on either day. In the acute phase of stroke, DMF administration attenuated lymphocyte infiltration, probably due to its stabilizing effect on the BBB. This highlights the potential of DMF as a therapeutic candidate for mitigating immune cell-driven damage in stroke.
RBM20 mutations account for 3 % of genetic cardiomypathies and manifest with high penetrance and arrhythmogenic effects. Numerous mutations in the conserved RS domain have been described as causing dilated cardiomyopathy (DCM), whereas a particular mutation (p.R634L) drives development of a different cardiac phenotype: left-ventricular non-compaction cardiomyopathy. We generated a mutation-induced pluripotent stem cell (iPSC) line in which the RBM20-LVNC mutation p.R634L was introduced into a DCM patient line with rescued RBM20-p.R634W mutation. These DCM-634L-iPSC can be differentiated into functional cardiomyocytes to test whether this RBM20 mutation induces development of the LVNC phenotype within the genetic context of a DCM patient.
Idiopathic Pulmonary Fibrosis (IPF) is a progressive parenchymal lung disease with limited therapeutic treatments. Pathologically altered lung fibroblasts, called myofibroblasts, exhibit increased proliferation, migration, and collagen production, and drive IPF development and progression. Fibrogenic factors such as Platelet derived growth factor-BB (PDGF-BB) contribute to these pathological alterations. Endogenous counter-regulating factors are barely known. Published studies have described a protective role of exogenously administered C-type Natriuretic Peptide (CNP) in pathological tissue remodeling, for example in heart and liver fibrosis. CNP and its cyclic GMP producing guanylyl cyclase B (GC-B) receptor are expressed in the lungs, but it is unknown whether CNP can attenuate lung fibrosis by this pathway. To address this question, we performed studies in primary cultured lung fibroblasts.
To examine the effects of the CNP/GC-B pathway on PDGF-BB-induced collagen
production, proliferation, and migration in vitro, lung fibroblasts were cultured from wildtype control and GC-B knockout mice. Human lung fibroblasts from patients with IPF and healthy controls were obtained from the UGMLC Biobank. In RIA experiments, CNP, at 10nM and 100nM, markedly and similarly increased cGMP levels in both the murine and human lung fibroblasts, demonstrating GC-B/cGMP signaling. CNP reduced PDGF-BB induced proliferation and migration of lung fibroblasts in BrdU incorporation and gap closure assays, respectively. CNP strongly decreased PDGF-BB-induced collagen 1/3 expression as measured by immunocytochemistry and immunoblotting. Importantly, the protective actions of CNP were preserved in IPF fibroblasts. It is known that the profibrotic actions of PDGF-BB are partly mediated by phosphorylation and nuclear export of Forkhead Box O3 (FoxO3), a transcription factor downregulated in IPF. CNP prevented PDGF-BB elicited FoxO3 phosphorylation and nuclear exclusion in both murine and human control and IPF fibroblasts. CNP signaling and functions were abolished in GC-B-deficient lung fibroblasts.
Taken together, the results show that CNP moderates the PDGF-BB-induced activation and differentiation of human and murine lung fibroblasts to myofibroblasts. This effect is mediated CNP-dependent by GC-B/cGMP signaling and FoxO3 regulation. To follow up the patho-physiological relevance of these results, we are generating mice with fibroblast-restricted GC-B deletion for studies in the model of bleomycin-induced pulmonary fibrosis.